Polybius Capital

Co-Founder Alfred Shang serves as Chief Investment Officer and holds full discretion over portfolio construction. He makes decisions with analyst input and reports to a board that includes representation from the anchor family and the endowment LP. Co-Founder Bing Yuan, as CEO, runs operations and investor relations but does not vote on individual positions (per The Wall Street Journal, 2022).

Polybius sources private deals through the professional networks of its founders, who draw on relationships from D.E. Shaw and Temasek. The firm does not rely on an advisory board or formal scout network. Its small, senior team attends major academic and industry AI conferences directly, and it occasionally receives allocations from top-tier venture firms for capacity-constrained rounds.

Polybius is structured as a pooled investment vehicle that commingles capital from an Asian billionaire family, a university endowment, and a sovereign wealth fund. It is not a single-family office, but the anchor family's balance-sheet capital gives the fund a permanent-capital base that lets it simultaneously hold concentrated public positions and illiquid private stakes — a structure that blends hedge-fund concentration with family-office patience.

Polybius runs a single pooled vehicle with a multi-year lock-up. Public equities, private equity, and venture allocations sit within the same legal entity. Limited partners own a pro-rata share of the total portfolio rather than selecting exposure to individual sleeves.

Co-Founder Alfred Shang is a member of an Asian business family that provided seed capital. He does not manage the family's operating companies or its other financial assets. Polybius Capital is a legally separate management entity that earns fees on external capital alongside the family's own commitment, and external LPs have the same economic terms as the family (per Bloomberg, 2022).

Polybius avoids sectors where it cannot build a concentrated, conviction-weighted position. The firm has stated internally that it will not invest in pure-play cryptocurrencies, cannabis, or traditional defense contracting. It also avoids pre-revenue biotech, citing the binary risk profile as incompatible with its crossover mandate.

No. Polybius does not offer deal-by-deal co-investment rights to existing limited partners or external general partners. All private exposure is funded through the commingled vehicle, preserving the team's ability to allocate without coordinating the preferences of co-investment stakeholders.